Navigation Links
Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging
Date:6/15/2010

BERLIN and BERGISCH GLADBACH, Germany, June 16, 2010 /PRNewswire/ -- Miltenyi Biotec today announces the worldwide release of the Viscover(TM) product line, offering researchers an unrivaled range of preclinical contrast agents for small animal in vivo imaging.

Viscover marks the result of a fruitful collaboration between Miltenyi Biotec GmbH and nanoPET Pharma GmbH. Within this strategic alliance, Miltenyi Biotec is responsible for the distribution of Viscover products developed and manufactured by nanoPET Pharma. The current Viscover portfolio comprises twenty-one contrast agents for the preclinical imaging modalities MRI, CT, Optical Imaging, Ultrasound and SPECT/PET, and this number is set to increase soon.

"This partnership offers researchers a unique and powerful portfolio of small animal in vivo imaging agents," explains Stefan Miltenyi, CEO of Miltenyi Biotec. "Both nanoPET Pharma and Miltenyi Biotec are committed to serving the biomedical research community with innovative high-quality imaging products throughout the world."

Commenting on the collaboration, Andreas Briel, CEO of nanoPET Pharma GmbH, said: "This landmark partnership brings together Miltenyi Biotec's excellence in worldwide customer support with nanoPET's exclusive range of contrast agents. Our scientists have years of experience in biomedical imaging, gained through strong affiliations with commercial and academic bodies."

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding and medical progress by providing products and services for cellular therapies. With approx. 1100 employees in 18 countries, Miltenyi Biotec develops, manufactures, and commercializes innovations for both research and clinical applications. The portfolio provides integrated solutions for all areas covering sample preparation, cell separation, cell culture, flow cytometry, and molecular analysis.

Visit http://www.miltenyibiotec.com to learn more.

About nanoPET Pharma

Based in Berlin, nanoPET Pharma GmbH discovers and develops innovative pharmaceutical contrast agents for use with the complete range of preclinical imaging modalities. The comprehensive Viscover portfolio currently provides contrast agents for the MRI, CT, Ultrasound, Optical Imaging, SPECT and PET modalities.

    Visit http://www.viscover.com to discover more.

    Contact:

    Miltenyi Biotec
    Prof. Dr. Uwe Heinlein, Corporate Communications,
    Miltenyi Biotec GmbH, +49-2204-8306-6590,
    uweh@miltenyibiotec.de

    nanoPET Pharma
    Carolin Schlueter, Corporate Communications,
    nanoPET Pharma GmbH, +49-30-890-49-740,
    Carolin.Schlueter@nanopet.de


'/>"/>
SOURCE Miltenyi Biotec GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Come to ... Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , ... our staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': ...
(Date:4/24/2017)... Calif. (PRWEB) , ... April 24, 2017 , ... Donna ... topics, but she has not found any of them to be very practical. She ... to slowly and easily make changes in their health. It prompted her in writing ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Reflections of God’s Work”: an enlightening collection of ... is the creation of published author, Jerri Broglin, a survivor of great loss who ... this a great eye-opener for those searching for answers, as we are finding the ...
(Date:4/24/2017)... ... 24, 2017 , ... “The Saint with Trin, and Omega Station”: a triple ... the creation of published author, Chris Jackson. Chris Jackson grew up in Abilene, ... Dallas Independent School District teaching English. He is heavily involved in the youth group ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is ... The event will be held at 7:30 pm on May 10th at the University ... Copeland of Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert ...
Breaking Medicine News(10 mins):